Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 5—May 2025
CME ACTIVITY - Research
Nationwide Observational Case–Control Study of Risk Factors for Aerococcus Bloodstream Infections, Sweden
, Malin Inghammar, Magnus Rasmussen, and Torgny Sunnerhagen
Table 3
Multivariable models used in nationwide observational case–control study of risk factors for Aerococcus BSIs, Sweden, 2012–2016*
| Characteristics | First model |
Final model |
|||
|---|---|---|---|---|---|
| Adjusted odds ratio (95% CI) | p value | Adjusted odds ratio (95% CI) | p value | ||
| Previous treatment for infection,† mo | |||||
| Never | Referent | NA | Referent | NA | |
| 1–3 | 1.77 (1.28–2.45) | <0.001 | 1.88 (1.38–2.56) | <0.001 | |
| >3–9 | 1.15 (0.83–1.58) | 0.40 | 1.21 (0.89–1.65) | 0.23 | |
| >9–24 |
1.19 (0.90–1.59) |
0.22 |
1.22 (0.92–1.61) |
0.16 |
|
| Malignant disease, nonurologic | 1.40 (1.01–1.95) | 0.046 | 1.39 (1.00–1.93) | 0.052 | |
| Structural urologic conditions‡ | 2.05 (1.63–2.57) | <0.001 | 2.15 (1.72–2.68) | <0.001 | |
| Neurologic conditions |
2.74 (2.13–3.52) |
<0.001 |
2.89 (2.26–3.70) |
<0.001 |
|
| Hospital admissions | |||||
| None | Referent | NA | Referent | NA | |
| 1–2 | 1.80 (1.37–2.37) | <0.001 | 1.74 (1.34–2.25) | <0.001 | |
| 3–5 | 3.56 (2.46–5.14) | <0.001 | 3.50 (2.50–4.88) | <0.001 | |
| 6–10 | 4.30 (2.39–7.75) | <0.001 | 4.34 (2.57–7.66) | <0.001 | |
| >10 |
5.99 (2.08–17.2) |
<0.001 |
6.81 (2.51–18.5) |
<0.001 |
|
| Rheumatologic disease | 0.77 (0.57–0.01) | 0.061 | 0.77 (0.59–1.00) | 0.050 | |
| Kidney disease | 1.15 (0.80–1.66) | 0.4 | NA | NA | |
| Pulmonary conditions | 1.00 (0.75–1.34) | 0.98 | NA | NA | |
| Gastrointestinal conditions | 0.86 (0.63–1.16) | 0.33 | NA | NA | |
| Diabetes mellitus | 0.97 (0.72–1.29) | 0.81 | NA | NA | |
| Cardiovascular disease | 0.84 (0.65–1.08) | 0.18 | NA | NA | |
| No. prescribed drugs | 1.03 (1.00–1.05) | 0.019 | NA | NA | |
| Corticosteroid therapy | 0.72 (0.52–0.99) | 0.040 | NA | NA | |
*First model included variables that had univariable associations with aerococcal BSI. Age, sex, and county were included in the models but were hidden because matching on those variables prevented appropriate interpretation of their respective estimates. Likelihood-ratio tests and variance inflation analyses were used to guide progressive refinement of the model. BSI, bloodstream infection; NA, not applicable. †Time in months indicates when treatment for another infection occurred before the aerococcal BSI was detected. ‡Included urological malignancies.